GTx, Inc. (NASDAQ:GTXI) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Tuesday.

GTx (NASDAQ GTXI) traded down 21.95% during midday trading on Tuesday, reaching $4.80. The company’s stock had a trading volume of 2,785,101 shares. The firm’s market cap is $77.00 million. GTx has a 52 week low of $2.73 and a 52 week high of $11.19. The firm has a 50 day moving average price of $4.16 and a 200-day moving average price of $4.79.

GTx (NASDAQ:GTXI) last released its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.39) EPS for the quarter. On average, analysts forecast that GTx will post ($1.16) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/06/13/valuengine-upgrades-gtx-inc-gtxi-to-sell.html.

An institutional investor recently raised its position in GTx stock. Geode Capital Management LLC raised its stake in shares of GTx, Inc. (NASDAQ:GTXI) by 0.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,531 shares of the biopharmaceutical company’s stock after buying an additional 276 shares during the period. Geode Capital Management LLC owned approximately 0.25% of GTx worth $192,000 as of its most recent SEC filing. 9.25% of the stock is owned by institutional investors.

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.